Recent Quotes

"PMN designated PMN267 as its lead candidate for treatment of ALS."

— Steve Silver, Argus Research (7/6/22)
more >

"PMN's PMN310 potentially represents a best-in-class opportunity."

— Steve Silver, Argus Research (6/27/22)
more >

"We view PMN's path to clinical value inflection favorably."

— Steve Silver, Argus Research (4/13/22)
more >



Due to permission requirements, not all quotes are shown.